CWM
AMRX icon

Compass Wealth Management’s Amneal Pharmaceuticals AMRX Stock Holding History

Compass Wealth Management’s Portfolio AMRX Stock Details AMRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-200
Closed -$1.68K – 167
2025
Q1 		$1.68K Hold
200
– – ﹤0.01% 410
2024
Q4 		$1.58K Hold
200
– – ﹤0.01% 381
2024
Q3 		$1.66K Hold
200
– – ﹤0.01% 383
2024
Q2 		$1.27K Buy
+200
New +$1.27K ﹤0.01% 387

Other funds holding AMRX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Compass Wealth Management's AMRX Position: Q2 2025 in Review

Compass Wealth Management sold out of Amneal Pharmaceuticals (AMRX) in Q2 2025, closing a stake of 200 shares — an estimated $1.68K sold.

Compass Wealth Management first reported a position in AMRX in Q2 2024 and held it in 4 quarters. The position peaked at $1.68K in Q1 2025. 241 funds tracked by Wall St. Rank hold AMRX as of Q2 2025.

  • Compass Wealth Management reported no remaining Amneal Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Compass Wealth Management sold 200 Amneal Pharmaceuticals shares in Q2 2025, an estimated $1.68K.
  • Compass Wealth Management first reported a position in Amneal Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Compass Wealth Management's Amneal Pharmaceuticals position peaked at $1.68K in Q1 2025.
  • 241 funds tracked by Wall St. Rank held Amneal Pharmaceuticals as of Q2 2025.

Based on Compass Wealth Management's 13F filing for Q2 2025, filed 8 Aug 2025.